CIPRO
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CIPRO by Bayer is 12. Approved for plague, including pheumonic, septicemic plague and 25 more indications. First approved in 1990.
Drug data last refreshed 23h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cipro (ciprofloxacin) is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase, disrupting bacterial cell division. It treats a broad range of infections including respiratory, urinary, skin, joint, and sexually transmitted infections, as well as bioterrorism-related exposures like plague and anthrax. Cipro is available in injectable formulation with ~70% oral bioavailability and wide tissue distribution, particularly in genital and respiratory tissues.
LOE Approaching
Product approaching loss of exclusivity with established generic competition; expect downsizing of commercial infrastructure and shift to specialty or indication-specific strategies.
Mechanism of Action
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see ]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.…
Worked on CIPRO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.